Focus on correcting the balance between proteases and antiproteases rather than the focus on actual levels of AAT may explain possible beneficial effects of AAT augmentation therapy in non-deficient individuals with cystic fibrosis and pneumonia, where AAT inhalation led to elastase inhibition and a reduction in the downstream effects of inflammation [25]. This evidence concerns the gene SERPINA1 and susceptibility to pneumonia measurement.